A major grant from the Bill & Melinda Gates Foundation has been made for a research programme to develop novel test protocols to accelerate development and bring to market, the next generation of vector control products.
Humans face hundreds of decisions every day. But we’re not alone. Even the tiniest viruses also make decisions, and scientists are researching how they do so, to help lead to better treatments for some diseases. A team at Texas A&M AgriLife Research discovered how the lambda phage decides what actions to take in its host, the E. coli bacterium.
A new Zika vaccine candidate has the potential to protect against the virus with a single dose, according to a research team led by scientists from the Perelman School of Medicine at the University of Pennsylvania. As reported in Nature this week, preclinical tests showed promising immune responses in both mice and monkeys.
Saint Louis University scientists aim to advance our understanding of how the hepatitis B virus replicates in order to develop a new drug that could cure the viral infection.
Malaria is still a global scourge, killing mostly children in tropical regions. Developing an affordable vaccine that can stay stable without refrigeration is a challenge. Now, a Weizmann Institute lab has reprogrammed proteins in such a way that they could lead to an inexpensive vaccine that can be stored at room temperature.
Researchers led by the Johns Hopkins Bloomberg School of Public Health have identified a mechanism by which the chikungunya virus infects healthy cells and controls how severe the disease it causes will be, a mechanism they believe can be found in a number of other related viruses for which there are no treatments or licensed vaccines.
NDSU forms collaborative relationships with local organizations to serve the state’s citizens. The NDSU Center for Immunization Research and Education works closely with health care providers to improve the state’s immunization rates.
Approximately 500 million people around the world are infected with the genital herpes virus known as herpes simplex virus 2 (HSV2). A vaccine that could bring an end to this global pandemic is needed desperately, yet no candidate vaccine has ever performed well in clinical trials. Now scientists in the Perelman School of Medicine at the University of Pennsylvania have shown that a new type of vaccine provides powerful protection in standard guinea pig and monkey models of HSV2 infection.
Recognizing a critical need to improve national vaccination rates for the human papillomavirus (HPV), UC Davis Comprehensive Cancer Center has again united with each of the 69 National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the U.S. Centers for Disease Control and Prevention (CDC)
The Georgia State University Research Foundation has entered into a research collaboration agreement with GeoVax Labs, Inc., a Georgia-based biotechnology company developing human vaccines, to advance development of a therapeutic vaccine for treatment of chronic Hepatitis B infections.
Vaccines are an important part of routine healthcare for adults, seniors and women who are pregnant. Older adults and seniors need protection against infectious illnesses just like children do. Dr. Cathleen Veach lists the four most important vaccines for adults.
Recognizing a critical need to improve national vaccination rates for the human papillomavirus (HPV), Yale Cancer Center has again united with each of the 69 National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention (CDC).
Every year in India, about 20,000 people die from rabies. Most of the victims are children. Nearly all of the deaths occur after victims are bitten by rabid dogs. For years, experts have debated the best strategy to reduce this burden. Now, a new study has identified a cost-effective way to reduce death due to rabies.
Mayo Clinic Cancer Center today joined with 69 National Cancer Institute-designated cancer centers in issuing a joint statement supporting updated HPV vaccination guidelines from the Centers for Disease Control and Prevention (CDC).
More than a decade after the HPV vaccine was deemed both safe and effective by the FDA for preventing several types of cancer, the vaccine is still underused by those who could benefit.
Perlmutter Cancer Center at NYU Langone Medical Center is again joining with each of the 69 National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement to increase vaccination against the human papillomavirus (HPV).
As national vaccination rates for the human papillomavirus (HPV) remain low, The University of Texas MD Anderson Cancer Center has again united with the 68 other National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement endorsing the recently revised vaccination recommendations from the Centers for Disease Control and Prevention (CDC).
Immunotherapy is a fast growing area of cancer research. It involves developing therapies that use a patient’s own immune system to fight and kill cancer. Moffitt Cancer Center is working on a new vaccine that would help early-stage breast cancer patients who have HER2 positive disease.
An international group of researchers associated with the World Health Organization has published its final report on the Ebola vaccine trial in Guinea, finding that the vaccine is a safe and effective way to prevent Ebola infection.
An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to a new study that included researchers from the University of Maryland School of Medicine.
A new study led by scientists at The Scripps Research Institute (TSRI) is the first to show exactly how the drug Arbidol stops influenza infections. The research reveals that Arbidol stops the virus from entering host cells by binding within a recessed pocket on the virus.
Researchers at the Icahn School of Medicine at Mount Sinai are working on the basic science that lays the groundwork to finding a way to treat and prevent the Zika virus, a global health risk.
City of Hope patient Susan Young has had a remarkable response to a potentially revolutionary new treatment, a combination of the p53 cancer vaccine and a drug that blocks a specific cancer-aiding protein.
In a bid to better understand the gene expression patterns that control T cell activity, researchers at the La Jolla Institute for Allergy and Immunology mapped genome-wide changes in chromatin accessibility as T cells respond to acute and chronic virus infections.
As scientists race to create a vaccine for the Zika virus, new research from the University of Georgia suggests almost half of Americans wouldn’t be interested in getting the shot even if public health officials recommended it for them.
New genetic research from an international team including McMaster University, University of Helsinki, Vilnius University and the University of Sydney, suggests that smallpox, a pathogen that caused millions of deaths worldwide, may not be an ancient disease but a much more modern killer that went on to become the first human disease eradicated by vaccination.
A personalized cancer vaccine markedly improved outcomes for patients suffering from acute myeloid leukemia (AML), a potentially lethal blood cancer, in a clinical trial led by investigators at Beth Israel Deaconess Medical Center (BIDMC). The product of a long-term collaboration among investigators at the Cancer Center at BIDMC and Dana-Farber Cancer Institute, the vaccine stimulated powerful immune responses against AML cells and resulted in protection from relapse in a majority of patients, the team of researchers reported today in Science Translational Medicine.
In a new study, researchers have modified a rabies virus, so that it has a protein from the MERS virus; this altered virus works as a 2-for-1 vaccine that protects mice against both Middle East Respiratory Syndrome (MERS) and rabies.
A team of researchers led by Yoshihiro Kawaoka, professor of pathobiological sciences at the University of Wisconsin–Madison School of Veterinary Medicine, has developed technology that could improve the production of vaccines that protect people from influenza B.
Americans are split on getting an annual flu shot, with four out of 10 having done so in the past year and around half saying they had already received or were planning to get the vaccine this year, according to new national survey data analyzed by University of Georgia researchers.
Flu cases are being reported in Maryland and across the country, and experts at the Johns Hopkins University School of Medicine expect to see numbers continue to rise. To prevent the flu, Johns Hopkins experts say everyone 6 months and older should get vaccinated against the influenza virus every year.
Scientists at The Scripps Research Institute (TSRI) have developed a vaccine that blocks the pain-numbing effects of the opioid drugs oxycodone (oxy) and hydrocodone (hydro) in animal models.
The Wistar Institute and Man’s Best Friend Therapeutics are pleased to announce a new collaboration that leverages Wistar’s groundbreaking vaccine research and development with MBFT’s expertise in developing animal health products.
The American Association of Pharmaceutical Scientists (AAPS) is pleased to announce the elevation of nine recipients to Fellow, one of the highest honors given to members of the association. Each year, AAPS elevates a few members to Fellow in recognition of their professional excellence in fields relevant to AAPS’s mission: to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health.
Typhoid fever remains a serious global problem: it kills almost a quarter of a million people annually. To help promote typhoid vaccines, the Bill & Melinda Gates Foundation has given a $36.9 million grant to the University of Maryland School of Medicine Center for Vaccine Development (CVD). The project is a partnership with the Oxford Vaccine Group and PATH.
A study led by researchers at Beth Israel Deaconess Medical Center (BIDMC), in collaboration with scientists at Walter Reed Army Institute of Research (WRAIR), Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson and Gilead Sciences, Inc., has demonstrated that combining an experimental vaccine with an innate immune stimulant may help lead to viral remission in people living with HIV. In animal trials, the combination decreased levels of viral DNA in peripheral blood and lymph nodes, and improved viral suppression and delayed viral rebound following discontinuation of anti-retroviral therapy (ART). The research team’s findings appeared online today in the journal Nature.
In this preclinical study, 100 percent of the animal models were protected from Zika after vaccination followed by a challenge with the Zika virus. In addition, they were protected from degeneration in the cerebral cortex and hippocampal areas of the brain, while the other cohort showed degeneration of the brain after Zika infection.
For the first time, scientists have prevented urinary tract infections in mice by vaccinating them with tiny molecules that UTI bacteria usually use to grab iron from their host and fuel the growth of bacteria in the bladder.
Some patients with rare primary immunodeficiency disorders may be at risk for infection by rubella virus, and possibly serious skin inflammation, after receiving the rubella vaccine, usually administered as part of the measles-mumps-rubella (MMR) vaccine. Although the vaccine for rubella (German measles) has an established record of safety and effectiveness in the general population, patients with severe deficiencies in their immune defenses may be susceptible to side effects from the vaccine.